AlphaCore Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

AlphaCore Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$935K	Sell	7,322 -328	-4%	-$40.9K	0.02%	403
2025 Q4	$933K	Buy	7,650 +7,210	+1,639%	+$827K	0.02%	436
2025 Q3	$44.1K	Sell	440 -100	-19%	-$9.01K	﹤0.01%	883
2025 Q2	$44.8K	Buy	540 +532	+6,650%	+$42.4K	﹤0.01%	825
2025 Q1	$675	Buy	+8	New	+$715	﹤0.01%	764
2024 Q1	–	Sell	-1,429	Closed	-$128K	–	392
2023 Q4	$128K	Buy	+1,429	New	+$106K	0.02%	240
2023 Q3	–	Sell	-100	Closed	-$8.32K	–	383
2023 Q2	$8.32K	Hold	100	–	–	﹤0.01%	305
2023 Q1	$7.62K	Buy	+100	New	+$8.3K	﹤0.01%	205
2021 Q4	–	Sell	-200	Closed	-$25K	–	135
2021 Q3	$25K	Buy	+200	New	+$25.8K	0.01%	93

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AlphaCore Capital's XBI Position: Q1 2026 in Review

AlphaCore Capital reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 4.3% in Q1 2026, selling an estimated $40.9K and leaving 7,322 shares worth $935K. The position accounts for 0.02% of the portfolio, ranked #403.

AlphaCore Capital first reported a position in XBI in Q3 2021 and has held it in 9 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

AlphaCore Capital held 7,322 shares of State Street SPDR S&P Biotech ETF worth $935K as of Q1 2026.
AlphaCore Capital sold 328 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $40.9K.
State Street SPDR S&P Biotech ETF made up 0.02% of AlphaCore Capital's portfolio in Q1 2026, its #403 holding.
AlphaCore Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and has held it in 9 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.